Clinical Trial

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-01; most recent amendment 2026-01-05.
Status change: Not Yet Recruiting → Recruiting 2024-10-14
Trial Details
NCT Number NCT06298058
Lead Sponsor Shanghai Institute Of Biological Products
Collaborators: Shanghai Pulmonary Hospital, Shanghai, China
Conditions Advanced Solid Tumor
Enrollment 144 participants
Start Date 2024-05-09
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-07